FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0104 OMB Number: Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the investment Company Act of 1940											
Name and Address of Reporting Person* Cheng Andrew				vent Requiring (Year) 9	Statement		lame and Ticker or Trading Symbol s <u>Biopharma Corp</u> [ABUS]				
(Last) (First) (Middle) C/O ARBUTUS BIOPHARMA CORPORATION						Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director	10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)		
701 VETERANS CIRCLE Street) WARMINSTER PA 18974						Officer (give title below)	Other (specify below)		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount o (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
Expiration				2. Date Exerc Expiration Da (Month/Day/Y	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion Exercise Prior Derivative	ce Form: Direct (D) or	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
				Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Security		

Explanation of Responses:

Remarks:

No securities are beneficially owned.

/s/ David C. Hastings as attorney-in-fact for Andrew Cheng

08/20/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

* If then the form is filed by more than one reporting person, see Instruction 5 (b)(v).

* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, the undersigned's application for EDGAF (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4 and 5, in accordance with Se (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to (A) complete and execute any such Forms 3, 4 or 5 (B)

Know all by these presents, that the undersigned hereby constitutes and appoints the David C. Hastings, David Kille and James List of Arbutus Biopharma Corpor

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best:

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, neces.

The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the (
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned in Nutrices. Whereof, the undersigned has caused this Power of Attorney to be executed as of this 15th day of August, 2019.

/s/ Andrew Cheng Andrew Cheng